
Development and marketing of pharmaceuticals in the fields of oncology, cardiometabolism, and neurology.
+160,000
Total organizations analyzedAnalysis by axis
Access the detailed report with all sector benchmarks, in-depth competitive analysis and actionable recommendations.
Methodology: Score calculated according to 6 CSR themes (Carbon, Biodiversity, Circular Economy, Sustainable Investments, Governance, Social Impact)
Sources: Public data, CSR reports, documented initiatives, official databases
Last update: December 2025
This analysis is not yet available in English. Please see the French version.
A
The organization is among the top 5% of organizations with the most committed CSR communication, among comparable organizations.
Leading organizations
Daiichi Sankyo France
B
Development and production of pharmaceuticals in the fields of oncology, onco-hematology, and cardiology.
Chiesi SAS
B
Development and marketing of pharmaceuticals in respiratory, neonatology, transplantation, and rare diseases.
Takeda
B
Development and commercialization of innovative medicines in various therapeutic areas, including gastrointestinal diseases, rare diseases, plasma-derived therapies, oncology, neuroscience, and vaccines.
Initiatives identified among leaders
Lancement d'un plan d'amélioration global
“Chiesi SAS lance un plan d'amélioration global pou...” - Chiesi SASSoutenir les patients atteints de cancer
“Daiichi Sankyo France s'engage à soutenir les pati...” - Daiichi Sankyo FranceDéveloppement de programmes de responsabilité sociale
“Takeda développe des programmes de responsabilité ...” - Takeda64% of similar organizations communicate on CSR issues
+3443 initiatives collected from 100 similar organizations
Is your score incomplete? Update your CSR information and improve your positioning.
Claim this page
Updated data
Personalized recommendations
Access complete data, competitive analyses and actionable recommendations for your clients.
Comprehensive sector benchmarks
Competitive data
Ready-to-use reports